1-800-640-1211 | 973-6100 | TTY: 973-6142
268 Stillwater Ave, PO Box 422, Bangor, ME 04402-0422

Community Health Needs Assessment

Acadia Hospital and EMMC Clinical Research Center Recognized for Alzheimer’s Clinical Trial Leadership

Posted: 12/01/2015

Drug-Trial-Official-photo.jpgBangor, ME – Acadia Hospital was recently recognized for outstanding contributions to the NOBLE study, a Phase 2 clinical study of a drug called T-817 that may slow progression of Alzheimer’s disease (AD). Acadia partners with EMMC’s Clinical Research Center to provide grant and research support.

Toyama Chemical of Japan is sponsoring the study. The Associate Director of Toyama and T-817 Development Project Leader Hiroshi Kobayashi, made a personal visit to Acadia Hospital to meet staff involved in the clinical trial. “I had the pleasure of visiting some of our outstanding US sites, including Acadia Hospital, to learn more about how they were being so successful in recruiting study participants,” commented Kobayashi. “I have learned that Acadia Hospital has firm roots in the community and has developed good relationships with local providers and patients. I was particularly impressed by the great study team, led by Dr. Clifford Singer.”

An estimated five million people in the U.S. already suffer from Alzheimer’s, with those numbers growing at an alarming rate. However, no new drug has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s since 2003. The NOBLE study was launched to potentially help address this gap in treatment.

“This drug has the potential to be the first to actually slow the pace of mild to moderate Alzheimer’s,” said Dr. Singer. “We are heartened by the response we have had to date, and hope to continue to work closely with the NOBLE study team on the trial. It was a great honor to have Mr. Kobayashi make a personal visit to our study site, and we are pleased to know that our efforts have been recognized.”

In consultation with family caregivers, Acadia Hospital is now seeking eligible candidates for NOBLE. To be eligible to participate, people must be between 55 and 85 with mild-to-moderate Alzheimer’s disease, and have been taking certain Alzheimer’s medications for at least four months. For additional information on the NOBLE study, please visit: www.NOBLEstudy.org or contact Claudine Allen, RN at the EMMC Clinical Research Center 207-973-9013.

News Archive